Zoetis Inc. (ZTS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Zoetis (ZTS) reiterated its 6.5%-8% revenue growth target for 2025 at the Morgan Stanley Global Healthcare Conference, anticipating a slower second half due to challenging prior-year comparisons and expected new competition in dermatology, which is factored into guidance. The company underscored the animal health industry's resilience and its market leadership, driven by strong performance in key franchises like Simparica Trio and dermatology, alongside strategic expansion into alternative distribution channels. Zoetis remains confident in its pain management portfolio, addressing recent Librela sales challenges with a multi-pronged strategy and preparing for new long-acting pain product approvals, while highlighting a robust pipeline targeting multi-billion dollar opportunities in chronic kidney disease, oncology, and cardiology as key future growth drivers.

Analysis

Zoetis management reaffirmed its 2025 operational revenue growth guidance of 6.5% to 8%, signaling confidence but also managing near-term expectations for a second-half slowdown. This moderation is attributed to challenging prior-year comparisons, particularly a 15% growth in Q3 2024 for companion animal products, and the anticipated Q4 launch of a competitor in the dermatology space, the impact of which has been factored into guidance. The company's long-term growth thesis remains intact, underpinned by its consistent outperformance of the broader animal health market (8% vs. 5% CAGR since 2013) and significant untapped potential in core franchises. Key growth runways include parasiticides, where triple-combinations now represent 45% of the oral market, and dermatology, where 20 million pets remain undertreated. A critical strategic element is the successful expansion into alternative channels like retail and e-commerce, which now account for 40% of U.S. sales for key products like Simparica Trio and Apoquel, driving compliance and partially insulating the business from veterinary visit trends. While acknowledging that the Librela launch has underperformed expectations due to social media headwinds, management outlined a clear recovery plan involving new Phase IV studies and enhanced education. The most significant long-term value driver is the pipeline, with major approvals expected annually, targeting multi-billion dollar opportunities in new therapeutic areas like chronic kidney disease ($3-4B market), oncology ($1.7B+), and cardiology.

Key Decisions for Investors

• Investors should model for a moderated growth rate in the second half of 2025, consistent with management's guidance, while monitoring the impact of the expected dermatology competitor launch in the fourth quarter.
• The turnaround of the Librela franchise is a key near-term catalyst; watch for initial data from Phase IV studies starting in Q4 2025 and management's execution on its multi-pronged commercial strategy to gauge its return to growth.
• Evaluate the durability of the core portfolio, as the company's ability to defend its leading share in parasiticides and dermatology against new entrants is a critical test of its commercial excellence and a key indicator for future performance.
• The long-term investment thesis hinges on the successful execution of the product pipeline; focus on upcoming regulatory milestones for long-acting pain products and the development progress in the high-potential renal, oncology, and cardiology markets.